Royce & Associates LP grew its stake in shares of Abacus Life, Inc. (NASDAQ:ABL - Free Report) by 339.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,306,431 shares of the company's stock after acquiring an additional 1,009,431 shares during the period. Royce & Associates LP owned about 1.35% of Abacus Life worth $10,229,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently modified their holdings of ABL. Geneos Wealth Management Inc. acquired a new position in Abacus Life in the fourth quarter worth about $110,000. Richard W. Paul & Associates LLC lifted its holdings in Abacus Life by 7.5% during the 4th quarter. Richard W. Paul & Associates LLC now owns 41,836 shares of the company's stock worth $328,000 after buying an additional 2,934 shares during the last quarter. Charles Schwab Investment Management Inc. acquired a new position in shares of Abacus Life in the 3rd quarter worth approximately $614,000. Evernest Financial Advisors LLC increased its holdings in shares of Abacus Life by 63.8% in the 4th quarter. Evernest Financial Advisors LLC now owns 110,250 shares of the company's stock valued at $863,000 after acquiring an additional 42,950 shares during the last quarter. Finally, Geode Capital Management LLC raised its position in shares of Abacus Life by 439.6% during the 3rd quarter. Geode Capital Management LLC now owns 171,917 shares of the company's stock valued at $1,741,000 after acquiring an additional 140,054 shares in the last quarter.
Abacus Life Stock Performance
Shares of NASDAQ ABL traded up $0.22 during mid-day trading on Friday, hitting $7.64. The company had a trading volume of 1,156,260 shares, compared to its average volume of 136,838. Abacus Life, Inc. has a 12 month low of $6.75 and a 12 month high of $12.65. The stock has a market cap of $738.37 million, a price-to-earnings ratio of -42.44 and a beta of 0.14. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.29 and a quick ratio of 1.29. The firm's 50 day simple moving average is $7.60 and its two-hundred day simple moving average is $8.41.
Wall Street Analysts Forecast Growth
Separately, B. Riley decreased their price objective on shares of Abacus Life from $17.00 to $15.00 and set a "buy" rating for the company in a report on Tuesday, January 7th. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Abacus Life currently has an average rating of "Buy" and an average price target of $14.30.
Read Our Latest Report on ABL
About Abacus Life
(
Free Report)
Abacus Life, Inc operates as an alternative asset manager specializing in life insurance products. It purchases life insurance policies from consumers seeking liquidity and manages policies over time via trading, holding, and/or servicing. The company was founded in 2004 and is based in Orlando, Florida.
Featured Articles
Before you consider Abacus Life, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abacus Life wasn't on the list.
While Abacus Life currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
